Congress Materials – Rheumatology Convergence Congress (ACR 2026)
2025 Rheumatology Convergence Congress | Nov 6-11 | Orlando, FL
Achievement of DAPSA/cDAPSA Low Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis Across Participant Subgroups in APEX
Christopher T. Ritchlin, Laura C. Coates, Philip J. Mease, Alexa P. Kollmeier, Weihong Hu, Katie Packard, Soumya D. Chakravarty, Stacey Fitch, Karissa Lozenski, Alexis Ogdie, Proton Rahman
This document will be available on Nov 7th 2026
Age at Onset and Its Association With Damage Accrual in Systemic Lupus Erythematosus (SLE): Insights From 5 Registries in the Lupus Federated Data Network (LupusNet)
Kaleb Michaud, Sarah Gasman, Federico Zazzetti, Ashley Orillion, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Reyhan Sonmez, Erika Noss, Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, Victor Pimentel-Quiroz, Guillermo A. Pons-Estel, Diana C. Fernández-Ávila, Carmen Funes Soaje, Henrique Ataide Mariz, Edgard Torres dos Reis-Neto, Carlos Alberto Cañas Davila, Gerardo Quintana-Lopez, Miguel Ángel Saavedra Salinas, Margarita Portela Hernández, Claudia Mora-Trujillo, Patricia Katz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Laniyati Hamijoyo, Yeong-Jian Jan Wu, Yasuhiro Katsumata, Iñigo Rúa-Figueroa, José María Pego-Reigosa, Raúl Menor Almagro, Jaime Calvo Alén, María Galindo-Izquierdo, Zulema Plaza, Fernando Sánchez-Alonso
This document will be available on Nov 7th 2026
Anti-C1q and Anti-dsDNA Antibodies Centrally Assessed Predict Renal Involvement in SLE Patients from the GLADEL 2.0 Cohort
Romina E. Nieto, Gricel Maita Romero, Carmen Funes Soaje, Veronica Gabriela Savio, Verónica Saurit, Lucila García, Boris Kisluk, Rosana Quintana, María Constanza Bertolaccini, Wilfredo Patiño Grageda, María de los Ángeles Gargiulo, Cecilia Pisoni, Vitalina Sousa Barbosa, Odirlei Andre Monticielo, Ángela Luzia Branco Pinto Duarte, Laissa Cristina Alves Alvino, Eduardo F. Borba, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Loreto Massardo, Gustavo Aroca, Carlos A. Cañas, Gerardo Quintana-López, Valentina Perez Jiménez, José Maximiliano Martínez Pérez, Reyna Elizabeth Sánchez-Briones, Mario Pérez Cristóbal, Fragoso-Loyo Hilda, Luis M. Amezcua-Guerra, Ignacio García Valladares, Carlos Abud Mendoza, Luciana Yulliet Gaytan García, Isabel Acosta Colman, Marcos Aurelio Vazquez, Claudia Mora-Trujillo, Manuel F. Ugarte-Gil, Katiuzka Zuñiga Corrales, Teresandris Polanco Mora, Martin Rebella, Ana Carolina Ralle, Alvaro Danza, Luciana Parente Costa Seguro, Carlos Enrique Toro-Gutierrez, Paola Pirruccio, Brooke Holloway, Mary Ann Aure, Carmen Andalucia, Savino Sciascia, Ashley Orillion, Federico Zazzetti, Guillermo Pons-Estel
This document will be available on Nov 7th 2026
Assessing the Patient Experience of Nipocalimab: Exit Interviews From the Phase 2 Randomized Placebo-Controlled Study in Sjogren’s Disease
Ghaith Noaiseh, Jacques Eric Gottenberg, Jennifer Clegg, Harman Dhatt, Kayla Scippa, Traci Abraham, Coleen del Rosario, Jonathan J. Hubbard, Kim Campbell, Claire Burbridge
This document will be available on Nov 7th 2026
Baseline Characteristics and 12-Month Effectiveness of Guselkumab and IL-17 Inhibitors Among Participants With Oligoarticular Psoriatic Arthritis in the Global PsABIOnd Study
Frank Behrens, Mohamed Sharaf, Stefan Siebert, Ennio Lubrano, Ruben Queiro Silva, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Enrique R. Soriano, Proton Rahman, Mitsumasa Kishimoto, Laure Gossec
This document will be available on Nov 7th 2026
Biomarker-Driven Insights From the Phase 2a AFFINITY Study Evaluating Guselkumab + Golimumab Combination Therapy Versus Guselkumab Monotherapy in Psoriatic Arthritis
Iain B. McInnes, Loqmane Seridi, Christopher T. Ritchlin, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Karissa Lozenski, Soumya D. Chakravarty, Eric Wadman, Carolyn Cuff, Matthew J. Loza, Warner Chen, Sheng Gao, Lianne S. Gensler, Philip J. Mease, Danielle Murphy, Jose U. Scher
This document will be available on Nov 11th 2026
Biomarker-Driven Insights to Clinical Response With Nipocalimab: A Phase 2 Randomized Trial for Sjögren’s Disease
Hal Scofield, He Li, Jacques-Eric Gottenberg, David Galbraith, Keying Ma, Lynn Tomsho, Chris Sisk, Matthew J. Loza, Jonathan J. Hubbard, Kim Campbell, Dawn Waterworth, Sheng Gao, Carolyn Cuff, Steven Leonardo, Kathy Sivils
This document will be available on Nov 7th 2026
ClinESSDAI Versus ESSDAI for Assessing Treatment Effects in Sjögren’s Disease: Findings From the Phase 2 DAHLIAS Trial of the FcRn Blocker Nipocalimab
Raphaèle Seror, Federico Zazzetti, Jonathan J. Hubbard, Soumya D. Chakravarty, Kim Campbell, Angelina Villasis-Keever, Roy van Heesbeen, Tom Thomas, Kathy Sivils, Sarah S. McCoy
This document will be available on Nov 7th 2026
Disease Activity, Organ Damage, and Treatment Exposaure in Systemic Lupus Erythematosus With Neuropsychiatric Involvement: Insights From the Lupus Federated Data Network (LupusNet)
Bernardo Pons-Estel, Carla Gobbi, María Constanza Bertolaccini, Nilzio Antonio da Silva, Iris Guerra Herrera, Carlos lberto Cañas, Yelitza C. González-Bello, Carlos Abud Mendoza, Carina Pizzarossa, Joaquín Martínez Serventi, Marta Domínguez-Álvaro, Jaime Calvo Alén, Antonio Fernández-Nebro, María Galindo-Izquierdo, Raúl Menor Almagro, Javier Narváez, Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, Victor Pimentel-Quiroz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Laniyati Hamijoyo, Yeong-Jian Jan Wu, Yasuhiro Katsumata, Carolina Bobadilla Mendez, Sarah Gasman, Catherine Yount, Anna Sheahan, Joerg Ermann, Stephen Fortin, Michel van Speybroeck, Reyhan Sonmez, Federico Zazzetti
This document will be available on Nov 7th 2026
Disease Burden, Fragmented Care and Healthcare Utilization in Sjögren’s Disease Compared With Rheumatoid Arthritis
Nora Sandorfi, Alexander Keenan, Elizabeth Adamson, Federico Zazzetti, Soumya D. Chakravarty, Debbie Goldschmidt, Sakshi Sethi, Jessica Smith, Esen K. Akpek
This document will be available on Nov 7th 2026
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior Tumor Necrosis Factor Inhibitor Through 1 Year of the SOLSTICE Study
Alice B. Gottlieb, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Soumya D. Chakravarty, Yanli Wang, Bea Rivard, Yevgeniy Krol, Stacey Fitch, Alexis Ogdie
This document will be available on Nov 7th 2026
Efficacy and Safety of Nipocalimab in Participants With Idiopathic Inflammatory Myopathies: Results From the Phase 2 SPIREA Trial Through 52 Weeks
Rohit Aggarwal, Hector Chinoy, Jiří Vencovský, Hitoshi Kohsaka, Mazen M. Dimachkie, Lisa Christopher-Stine, Amuche Anakor, Mallikarjun Metukuri, Shu Li, Rawan Rupnow, Kellen Cresswell, Jocelyn H. Leu, Lucas Poon, Vani Lakshminarayanan, Ricardo Rojo Cella, Federico Zazzetti, Harman Dhatt, Zoltán Griger
This document will be available on Nov 8th 2026
Efficacy and Safety of Subcutaneous Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis: Results of the Open-Label, Phase 3 PSUMMIT-Jr Study Through Week 52
Hermine Brunner, Daniel P. Hawley, Ozgur Kasapcopur, Sandrine Compeyrot-Lacassagne, Hafize Emine Sönmez, Berta Paula Magallares López, Ozge Basaran, Alejandro Brigante, Samundeeswari Deepak, Giovanni Filocamo, Kerstin Nott, Sarah Ringold, Samantha Howard, Valerie Smith, Katherine Berezny, Thomas N. Kakuda, Jocelyn H. Leu, Daniel J. Lovell, Alberto Martini, Nicolino Ruperto, on behalf of the Pediatric Rheumatology Collaborative Study Group, PRCSG, and Paediatric Rheumatology International Trials Organisation, PRINTO
This document will be available on Nov 7th 2026
Four-Week Changes in Collagen Degradation Biomarkers are Prognostic of 24-Week Clinical Response in Psoriatic Arthritis: A Biomarker-Guided Stratification Approach
Rikke Malmkvist, Anne-Christine Bay-Jensen, Dovile Sinkeviciute, Simon Francis Thomsen, Morten Asser Karsdal, Karissa Lozenski, Loqmane Seridi, Sheng Gao, Warner Chen, Danielle Murphy
This document will be available on Nov 7th 2026
Guselkumab Efficacy on Improvements in American College of Rheumatology Response Components and Association With Structural Damage Progression in Participants With Active and Erosive Psoriatic Arthritis: Results From a Phase 3b, Randomized Double-Blind, Placebo-Controlled Study
Proton Rahman, Laura C. Coates, Philip J. Mease, Stacey L. Fitch, Soumya D. Chakravarty, Alexa P. Kollmeier, Weihong Hu, Karissa Lozenski, Frank R. Wellborne, Arthur Kavanaugh, Christopher T. Ritchlin
This document will be available on Nov 7th 2026
Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available on Nov 7th 2026
Healthcare Resource Utilization, Including Dental Care, Before and After Sjögren's Disease Diagnosis in the Veterans Affairs Health Care System
Esen K. Akpek, Alexander Keenan, Elizabeth Adamson, Federico Zazzetti, Soumya D. Chakravarty, Debbie Goldschmidt, Sakshi Sethi, Jessica Smith, Nora Sandorfi
This document will be available on Nov 7th 2026
Impact on Productivity of Sjögren’s Disease in Swedish Patients - A Nationwide Cohort Study Between 2006 and 2022
Johannes Mofors, Ying Qu, Federico Zazzetti, Jakob Börsum, Kavita Gandhi, Mikael Själin, Peter Olsson
This document will be available on Nov 7th 2026
Improvement in Executive Function Following Nipocalimab Treatment in Patients With Sjögren’s Disease: A Randomized Clinical Trial
Stefan Avey, Michael Deman, Kim Campbell, Nikolay V. Manyakov, He Li, Kathy Sivils, Steven Leonardo, Keying Ma, Harman Dhatt, Paul Maruff, Jonathan J. Hubbard, Wan-Fai Ng
This document will be available on Nov 9th 2026
Incidence Comorbidities and Causes of Mortality in Patients With Sjögren Disease in the Swedish Population Between 2006-2022
Johannes Mofors, Ying Qu, Federico Zazzetti, Jakob Börsum, Coralie Bouillot, Odalis Asin-Milan, Mikael Själin, Peter Olsson
This document will be available on Nov 7th 2026
Intravenous Cyclophosphamide Versus Mycophenolate Mofetil for Induction Therapy in Incident Lupus Nephritis: Data From a Multi-Ethnic, Multinational Latin American Cohort (GLADEL 2.0)
Victor R. Pimentel-Quiroz, Guillermina Harvey, Marina Scolnik, Carmen Funes Soaje, Carla Gobbi, Verónica Saurit, Valeria Arturi, Leonel Ariel Berbotto, Rosana Quintana, Luciana González Lucero, Eduardo Kerzberg, Nicolás Pérez, Cecilia Pisoni, Vicente Juarez, Joaquín Martínez Serventi, Ana Carolina de Oliveira e Silva Montandon, Andrese Aline Gasparin, Henrique Ataide Mariz, Evandro Klumb, Eduardo F. Borba, Eloisa Bonfa, Edgard Torres dos Reis Neto, Iris Guerra Herrera, Milena Mimica Davet, Gustavo Aroca Martinez, Antonio Iglesias Gamarra, Carlos A. Cañas Davila, Gerardo Quintana-Lopez, Carlos Enrique Toro-Gutierrez, Mario Moreno Alvarez, Reyna Elizabeth Sánchez Briones, Margarita Portela Hernandez, Hilda Fragoso Loyo, Luis M. Amezcua-Guerra, Yelitza González Bello, Carlos Abud Mendoza, Jorge Antonio Esquivel-Valerio, Isabel Acosta Colman, Jhonatan Losanto, Claudia Mora Trujillo, Manuel F. Ugarte-Gil, Armando Calvo Quiroz, Roberto Muñoz Louis, Martin Rebella, Álvaro Danza, Federico Zazzetti, Ashley Orillion, Bernardo Pons-Estel, Luis Catoggio
This document will be available on Nov 7th 2026
Longitudinal Disease Activity, Damage Accrual, and Treatment Exposure in Systemic Lupus Erythematosus With Lupus Nephritis: Insights From the Lupus Federated Data Network (LupusNet)
Guillermo J. Pons-Estel, Verónica Saurit, Leonel Berbotto, Lorena Verónica Suáres, Elisa Martins N. Albuquerque, Edgard Torres dos Reis-Neto, Miguel Ángel Saavedra Salinas, Yaneli Juárez-Vicuña, Jorge Esquivel, Carlos Enrique Toro-Gutierrez, José María Pego-Reigosa, Iñigo Rúa-Figueroa, Marta Domínguez-Álvaro, Antonio Fernández-Nebro, María Galindo-Izquierdo, Raúl Menor Almagro, Jaime Calvo Alén, Eva Tomero, Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, Victor Pimentel-Quiroz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Laniyati Hamijoyo, Yeong-Jian Jan Wu, Yasuhiro Katsumata, Carolina Bobadilla Mendez, Sarah Gasman, Catherine Yount, Anna Sheahan, Joerg Ermann, Stephen Fortin, Michel van Speybroeck, Reyhan Sonmez, Federico Zazzetti
This document will be available on Nov 7th 2026
Minimal Disease Activity at 12 Months With Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: Results From the Global PsABIOnd Study
Stefan Siebert, Mohamed Sharaf, Laure Gossec, Frank Behrens, Ennio Lubrano, Mitsumasa Kishimoto, Xenofon Baraliakos, Ruben Queiro Silva, Beatriz Joven, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Enrique R. Soriano, Proton Rahman
This document will be available on Nov 7th 2026
Model-Based PsO-PsA Bridging for PsA Dose Selection: A Case Study of the IL-17 Small Molecule Inhibitor JNJ-81241459
Dawei Song, Mehrdad Javidi, Philip Cooper, Selena Huang, Monica Leung, An Vermeulen, Weirong Wang, Vikash Sinha
This document will be available on Nov 7th 2026
Mortality and Loss of Life Expectancy in Patients With Sjögren Disease in Sweden: A Population-Based Study From 2006 to 2022
Peter Olsson, Ying Qu, Federico Zazzetti, Jakob Börsum, Kavita Gandhi, Mikael Själin, Johannes Mofors
This document will be available on Nov 7th 2026
Nipocalimab for Warm Autoimmune Hemolytic Anemia: Results From a Phase 2/3 Randomized Double-Blind Study
Guillermo J. Pons-Estel, Bruno Fattizzo, Irina Murakhovskaya, Yasutaka Ueda, Doug Schlichting, Kristen Sweet, Michael Zelasky, Jagriti Craig, Jocelyn Leu, Leona Ling, Sheryl Pease, Cathye Shu
This document will be available on Nov 11th 2026
Nipocalimab in SLE: First-in-Class Efficacy and Safety Results Demonstrating Proof of Concept for FcRn Blockade From a Phase 2 Study
Richard A. Furie, Ronald van Vollenhoven, Rafał Wojciechowski, Eric Morand, Guillermo J. Pons-Estel, George A. Karpouzas, Bart van Hartingsveldt, Robert W. Hoffman, Terence Rooney, Sheng Gao, Robert Gordon, Kim Hung Lo, Jocelyn H. Leu, Federico Zazzetti, Stanley J. Marciniak, Steven Leonardo, Keying Ma, Kathy Sivils, Leonard Dragone, Loqmane Seridi, Linda Okonkwo, Erika Noss, Fang Liu-Walsh, Michelle Petri
This document will be available on Nov 8th 2026
Non-Invasive Surveillance of the Presence of Lupus Nephritis and its Response to Therapy Using the RAIL Urine Biomarkers in the GLADEL Cohort
Guillermo Pons-Estel, Romina E. Nieto, Marina Scolnik, Carmen Funes Soaje, Paula Alba, Verónica Saurit, Valeria Arturi, María Emilia Sattler, Diana C. Fernández-Ávila, Luciana Gonzalez Lucero, Eduardo Kerzberg, Nicolás Perez, Micaela A. Cosatti, Ana Carolina O.S. Montandon, Andrese Aline Gasparin, Henrique de Ataíde Mariz, Evandro Mendes Klumb, Eduardo F. Borba, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Milena Mimica, Gustavo Aroca Martinez, Carlos A. Cañas, Gerardo Quintana, Valentina Perez Jiménez, Mario J. Moreno, Olga Lidia Vera-Lastra, Margarita Portela-Hernández, Hilda Fragoso-Loyo, Luis H. Silveira, Yelitza C. González-Bello, Carlos Abud-Mendoza, Luciana Yulliet Gaytan García, Isabel Acosta Colman, Patricia Langjahr, Claudia Mora-Trujillo, Manuel F. Ugarte-Gil, Armando Calvo, Roberto Muñoz-Louis, Martin Rebella, Vicente Juárez, Alvaro Danza, Luciana Parente Costa Seguro, John Jaramillo-Gallego, Joaquín Martínez Serventi, Ashley Orillion, Federico Zazzetti, Bin Huang, Chen Chen, Alyssa Sproles, Hermine Brunner, Bernardo Pons-Estel
This document will be available on Nov 7th 2026
Organ Damage and Its Relationship With Disease Activity in Systemic Lupus Erythematosus: Insights From the Lupus Federated Data Network (LupusNet)
Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, Victor Pimentel-Quiroz, José María Pego-Reigosa, Iñigo Rúa-Figueroa, Marta Domínguez-Álvaro, María Galindo-Izquierdo, Raúl Menor Almagro, Jaime Calvo Alén, Antonio Fernández-Nebro, Julia Martínez-Barrio, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Laniyati Hamijoyo, Yeong-Jian Jan Wu, Yasuhiro Katsumata, Mercedes García, Guillermo J. Pons-Estel, Eduardo Kerzberg, Micaela A. Cosatti, Odirlei Andre Monticielo, Iris Guerra Herrera, Gerardo Quintana-Lopez, Hilda Fragoso-Loyo, Armando Calvo, Vicente Juárez, Carolina Bobadilla Mendez, Sarah Gasman, Catherine Yount, Anna Sheahan, Joerg Ermann, Stephen Fortin, Michel van Speybroeck, Reyhan Sonmez, Federico Zazzetti
This document will be available on Nov 7th 2026
Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis
Yayoi Tada, Peter Foley, April W. Armstrong, Joseph F. Merola, Jessie Chang, Steven Fakharzadeh, Emmanouil Rampakakis, Yu-Huei Huang, Luis Puig, Richard G. Langley
This document will be available on Nov 7th 2026
Patient-Reported Outcomes in Participants With Active and Erosive Psoriatic Arthritis Receiving Guselkumab: Results Through Week 48 of a Phase 3b, Randomized Double-Blind, Placebo-Controlled Study
Proton Rahman, Philip J. Mease, Christopher T. Ritchlin, Elizabeth Adamson, Soumya D. Chakravarty, Alexa P. Kollmeier, Weihong Hu, Karissa Lozenski, Arthur Kavanaugh, Laura C. Coates
This document will be available on Nov 7th 2026
Persistence, Effectiveness, Safety, and Patient Reported Impact of Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: Full Population Results of the PsABIOnd Global Observational Study Over 12 Months
Laure Gossec, Mohamed Sharaf, Frank Behrens, Ennio Lubrano, Mitsumasa Kishimoto, Xenofon Baraliakos, Ruben Queiro Silva, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Enrique R. Soriano, Proton Rahman, Stefan Siebert
This document will be available on Nov 7th 2026
Pharmacodynamic Biomarkers in Biologic-Naïve Participants With Active and Erosive Psoriatic Arthritis: Results Through Week 48 From the Phase 3 APEX Study
Carolina Bobadilla Mendez, Proton Rahman, Christopher T. Ritchlin, Eric Wadman, Alexa P. Kollmeier, Karissa Lozenski, Carolyn Cuff, Matthew J. Loza, Sheng Gao, Philip J. Mease, Loqmane Seridi, Danielle Murphy
This document will be available on Nov 7th 2026
Pharmacodynamics of Nipocalimab, a Fully Human FcRn-Blocking Monoclonal Antibody, in Adults With Systemic Lupus Erythematosus: Results From a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (JASMINE-SLE)
Michelle Petri, Loqmane Seridi, Sheng Gao, Robert Gordon, Federico Zazzetti, Stanley J. Marciniak, Steven Leonardo, Kathy Sivils, Leonard Dragone, Linda Okonkwo, Erika Noss, Keying Ma, Ta-Ming Liu, Fang Liu-Walsh, Richard A. Furie
This document will be available on Nov 7th 2026
Pregnancy and Obstetric Outcomes in Systemic Lupus Erythematosus: Insights From the GLADEL 2.0 Cohort
Rosa Serrano Morales, Romina Nieto, Karen Roberts, Marina Scolnik, Carmen Funes Soaje, Paula Alba Moreyra, Verónica Saurit, Valeria Arturi, Maria Emilia Sattler, María Constanza Bertolaccini, Eduardo Kerzberg, Lorena Veronica Suarez, Micaela Cosatti, María Elena Crespo Espindola, Paola Pirruccio, Vitalina Barbosa, Guilherme Levi Três, Henrique Ataide Mariz, Evandro Klumb, Eduardo F. Borba, Luciana Seguro, Edgard Torres dos Reis Neto, Iris Guerra Herrera, Milena Mimica Davet, Gustavo Aroca Martinez, Valentina Pérez Jiménez, Carlos A. Cañas Davila, Juanita Ramirez-Mancera, Carlos Enrique Toro-Gutierrez, Mario Moreno Alvarez, Miguel A. Saavedra Salinas, Mario Pérez Cristóbal, Hilda Fragoso Loyo, Luis Silveira, Ignacio García-Valladares, Carlos Abud Mendoza, Jorge Antonio Esquivel-Valerio, Astrid Paats, Marcelo Barrios, Magaly Alva, Manuel F. Ugarte-Gil, Armando Calvo Quiroz, Roberto Muñoz Louis, Carina Pizzarossa, Álvaro Danza, Federico Zazzetti, Ashley Orillion, Guillermo Pons-Estel, Graciela S. Alarcón
This document will be available on Nov 7th 2026
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab Versus Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Pavithra Srinivas, Bruno Emond, Arthur Voegel, Yuxi Wang, Sinia Sareen, Helena Huang, Thanh Nguyen, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
This document will be available on Nov 7th 2026
Relationship Between IgG Levels and Infection Rates in Nipocalimab Treated Participants With Systemic Lupus Erythematosus (SLE) in the Phase 2 JASMINE-SLE Study
Richard A. Furie, Ricardo Rojo Cella, Robert Edwards, Bart van Hartingsveldt, Robert Gordon, Kim Hung Lo, Kefira Ke, Federico Zazzetti, Stanley J. Marciniak, Linda Okonkwo, Erika Noss, Fang Liu-Walsh, Michelle Petri
This document will be available on Nov 7th 2026
Safety of Guselkumab in Participants With Active Psoriatic Arthritis: Pooled Results From Four Phase 3, Randomized, Placebo-Controlled Trials
Atul Deodhar, Alexis Ogdie, Christopher T. Ritchlin, Iain B. McInnes, Soumya D. Chakravarty, Elizabeth Adamson, Prasheen Agarwal, Hunter Gomes, Tong Wang, Alice B. Gottlieb, Philip J. Mease
This document will be available on Nov 7th 2026
Systemic Treatment Patterns in Systemic Lupus Erythematosus (SLE): Associations With Disease Severity and Organ-Specific Activity Across 5 Registries in the Lupus Federated Data Network (LupusNet)
Guillermo A. Pons-Estel, Sarah Gasman, Federico Zazzetti, Ashley Orillion, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Reyhan Sonmez, Erika Noss, Manuel F Ugarte-Gil, Rocio V. Gamboa-Cardenas, Victor Pimentel-Quiroz, Romina Nieto, Marina Scolnik, Eduardo F. Borba, Loreto Massardo, Gustavo Aroca Martínez, Mario Javier Moreno Alvarez, Isabel Acosta Colman, Roberto Muñoz Louis, Álvaro Danza, Kaleb Michaud, Patricia Katz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Laniyati Hamijoyo, Yeong-Jian Jan Wu, Yasuhiro Katsumata, Iñigo Rúa-Figueroa, José María Pego-Reigosa, Raúl Menor Almagro, Jaime Calvo Alén, María Galindo-Izquierdo, Zulema Plaza, Fernando Sánchez-Alonso
This document will be available on Nov 7th 2026
Treatment Persistence and Effectiveness Across PsA Patient Subgroups Treated With Guselkumab and IL-17 Inhibitors: 12-Month Findings From the Global PsABIOnd Study
Laure Gossec, Mohamed Sharaf, Stefan Siebert, Frank Behrens, Mitsumasa Kishimoto, Ruben Queiro Silva, Carlo Selmi, Andres Chavarriaga, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Enrique R. Soriano, Proton Rahman, Ennio Lubrano
This document will be available on Nov 7th 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.